Last reviewed · How we verify
Pneumococcal conjugate vaccine GSK2830930A
Pneumococcal conjugate vaccine GSK2830930A is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 2 development.
At a glance
| Generic name | Pneumococcal conjugate vaccine GSK2830930A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers (PHASE1)
- Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pneumococcal conjugate vaccine GSK2830930A CI brief — competitive landscape report
- Pneumococcal conjugate vaccine GSK2830930A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Pneumococcal conjugate vaccine GSK2830930A
What is Pneumococcal conjugate vaccine GSK2830930A?
Pneumococcal conjugate vaccine GSK2830930A is a Biologic drug developed by GlaxoSmithKline.
Who makes Pneumococcal conjugate vaccine GSK2830930A?
Pneumococcal conjugate vaccine GSK2830930A is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is Pneumococcal conjugate vaccine GSK2830930A in?
Pneumococcal conjugate vaccine GSK2830930A is in Phase 2.